Replay Bio
Replay receives $1.5 million grant for its hypoimmunogenic technology platform
Replay developing uCell™, its universal, off-the-shelf, genomically rewritten, renewable compartment source hypoimmunogenic technology, with enactment from the Bill & Melinda Gates Foundation
uCell™ has the potential to democratize cell therapy by reducing cost-of-goods, facilitating access to high-impact cell therapy products for underserved communities around the world
uCell™ forms portion of Replay’s genomic medicine toolkit that encompasses a portfolio of potentially disruptive level technologies, including a high payload capableness HSV transportation platform, synHSV™, and a proprietary genome penning platform
uCell™ applicable to compartment therapy across a wide scope of therapeutic areas including cancer, infectious diseases, neurodegenerative diseases, and regenerative medicine
San Diego, California and London, UK, November 28, 2022 – Replay, a genome penning institution reprogramming biology by penning and delivering large DNA, contiguous announced that it has received a $1.56 cardinal assistance from the Bill & Melinda Gates Foundation to accelerate the improvement of uCell™, a proprietary hypoimmunogenic exertion platform.
Replay’s uCell™ level is an off-the-shelf, genomically rewritten, hypoimmunogenic exertion that allows allogeneic donor-derived superior cells and iPSCs (Induced Pluripotent Stem Cells) to beryllium made immune silent. The exertion is expected to substantially alteration the cost-of-goods of compartment therapies, amended merchandise measurement and consistency, alteration extended genome engineering, and successful the lawsuit of crab compartment therapy, alteration deeper objective responses and reduced relapse rates. uCell™ is anticipated to signifier the ground of respective off-the-shelf iPSC-derived immune compartment therapies applicable to a aggregate therapeutic areas, including crab and infectious diseases. The exertion is applicable to some the developed and processing worlds, with the anticipated reduced cost-of-goods improving equity of access.
Adrian Woolfson, Executive Chairman, President, and Co-Founder of Replay, commented: “Hypoimmunogenic exertion is the ‘holy grail’ of compartment therapy and the non-dilutive backing received from the Bill & Melinda Gates Foundation volition assistance accelerate the improvement of our uCell™ technology. It is expected to code galore of the cardinal challenges of compartment therapy, including scalability, the quality to present extended genomic modifications, and request to trim cost-of-goods. We are immensely grateful to the instauration and our investors for supporting Replay’s imaginativeness for the aboriginal of genomic medicine, which includes a absorption connected the improvement of high-impact and affordable compartment therapies that are accessible to some industrialized and agrarian communities.”
Lachlan MacKinnon, Chief Executive Officer, and Co-Founder of Replay, added: “Replay’s hypoimmunogenic exertion is the effect of a convergence of synthetic biology, computational design, and macromolecule engineering with iPS compartment technology. It volition alteration the Company to make a cosmopolitan off-the-shelf level successful a reliable, scalable, and cost-effective manner, and broaden the inferior and accessibility of compartment therapy, including regenerative medicine applications. The quality to reprogram hypoimmunogenic iPSCs with our precocious payload synHSV™ level volition unlock a differentiated acceptable of opportunities. As is the lawsuit with synHSV™, and fixed the substantive accidental successful the space, we program to advancement our uCell™ exertion done chiseled therapeutic area-focused merchandise companies.”
Professor Herman Waldmann, Co-inventor of uCELL™ and Emeritus Professor of Pathology astatine the Sir William Dunn School of Pathology astatine the University of Oxford, said: “As a doc scientist, it is encouraging to spot Replay beforehand the uCell™ platform, which has the imaginable to flooded galore of the existent limitations of compartment therapies. By making iPSCs immune soundless to make a cosmopolitan compartment with inferior arsenic a renewable root for compartment therapies, uCell™ has the imaginable to bring the benefits of this important therapeutic modality to patients crossed the world.”
Ends
About Replay
Replay is simply a genome penning company, which aims to specify the aboriginal of genomic medicine done reprogramming biology by penning and delivering large DNA. The Company has assembled a toolkit of disruptive level technologies – including a precocious payload capableness HSV platform, a hypoimmunogenic platform, and a genome penning level – to code the technological challenges presently limiting objective advancement and preventing genomic medicine from realizing its afloat potential. The Company’s hub-and-spoke concern exemplary separates exertion improvement wrong Replay from therapeutic improvement successful merchandise companies, which leverage the exertion platforms. For example, Replay’s synHSV™ technology, a precocious payload capableness HSV vector susceptible of delivering up to 30 times the payload of AAV, is utilized by Replay’s 4 cistron therapy merchandise companies, bringing large DNA treatments to diseases affecting the skin, eye, brain, and muscle. The Company has, additionally, established an enzyme penning merchandise institution engaging its evolutionary inference instrumentality learning and genome penning exertion to optimize functionality. Replay is led by a world-class squad of academics, entrepreneurs, and manufacture experts.
The Company raised $55 cardinal successful effect financing successful July 2022 and is supported by an planetary syndicate of investors that includes KKR, OMX Ventures, ARTIS Ventures, and Lansdowne Partners.
Replay is headquartered successful San Diego, California, and London, UK. For further accusation delight sojourn www.replay.bio and travel america connected LinkedIn and Twitter.
Contacts:
Replay
Dr Adrian Woolfson/Lachlan MacKinnon
Consilium Strategic Communications – Media relations
Amber Fennell/Tracy Cheung/Melissa Gardiner
English (US)